Is Now The Time To Buy Statera Biopharma Inc. (NASDAQ: STAB) Stock?

Statera Biopharma Inc. (NASDAQ:STAB) price is hovering lower on Tuesday, March 22, dropping -43.61% below its previous close.

A look at today’s price movement shows that the recent level at last check reads $0.59, with intraday deals fluctuating between $0.5753 and $0.6609. Taking into account the 52-week price action we note that the stock hit a 52-week high of $7.17 and 52-week low of $0.54. The stock subtracted -32.89% on its value in the past month.

Statera Biopharma Inc., which has a market valuation of $22.01 million, is expected to release its quarterly earnings report Nov 15, 2021.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give STAB a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.

The overview shows that STAB’s price is at present -50.89% off the SMA20 and -69.72% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 25.67, with weekly volatility standing at 15.01%. The indicator jumps to 19.40% when calculated based on the past 30 days. Statera Biopharma Inc. (NASDAQ:STAB)’s beta value is holding at 1.39, while the average true range (ATR) indicator is currently reading 0.11.

Turning out attention to how the Statera Biopharma Inc. stock has performed in comparison to its peers in the industry, here’s what we find: STAB’s stock is -43.61% on the day and -90.31% in the past 12 months, while Eli Lilly and Company (LLY) traded -1.49% in the latest session and is positioned 55.85% up on its price 12 months ago. Another comparison is with Sanofi (SNY) whose stock price is up 1.37% in the current trading session, and has flourished 3.37% over the past year. Also, Bristol-Myers Squibb Company (BMY) is currently showing down trend of -0.75% while its price kept floating at 12.10% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 1.14% in today’s early trading, with the Dow Jones Industrial also seeing a positive session on the day with 0.68%.

An analysis of the Statera Biopharma Inc. (NASDAQ:STAB) stock in terms of its daily trading volume indicates that the 3-month average is 751.86K. However, this figure increases on the past 10-day timeline to an average of 1.35 million.

Current records show that the company has 27.04M in outstanding shares. The insiders’ percentage holdings are 0.30% of outstanding shares while the percentage share held by institutions stands at 5.40%. The stats also highlight that short interest as of Feb 14, 2022, stood at 0.15 million shares, which puts the short ratio at the time at 0.86. From this we can glean that short interest is 0.43% of company’s current outstanding shares. Notably, we see that shares short in February fall slightly given the previous month’s figure stood at 0.24 million. But the -74.16% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Comment